Bausch + Lomb (NYSE: BLCO) assigns new directors to key board committees

Rhea-AI Filing Summary

Bausch + Lomb Corporation filed an amended current report to update board committee assignments for two recently appointed directors. The company had previously disclosed that Eduardo C. Alfonso, MD, and Steven H. Collis would join the board effective January 1, 2026.

The amendment states that, effective January 1, 2026, Dr. Alfonso will serve on the Science and Technology Committee and Mr. Collis will serve on the Talent and Compensation Committee. These changes clarify how the new directors will participate in the company’s governance structure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0001860742FALSEBausch & Lomb Corp00018607422025-12-172025-12-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

December 17, 2025

Date of Report (Date of the earliest event reported)

Bausch + Lomb Corporation

(Exact Name of Registrant as Specified in Its Charter)

Canada			001-41380			98-1613662
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(I.R.S. Employer Identification Number)

520 Applewood Crescent

Vaughan, Ontario

Canada L4K 4B4

(Address of Principal Executive Offices)(Zip Code)

(905) 695-7700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Shares, No Par Value			BLCO			New York Stock Exchange			Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 17, 2025, Bausch + Lomb Corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) regarding the appointment of Eduardo C. Alfonso, MD and Steven H. Collis to its board of directors (the “Board”), effective January 1, 2026. This Amendment No. 1 to the Initial 8-K is being filed to report that on December 22, 2025, the Board appointed Dr. Alfonso as a member of its Science and Technology Committee and Mr. Collis as a member of its Talent and Compensation Committee, each appointment effective January 1, 2026.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BAUSCH + LOMB CORPORATION
By:			/s/ A. Robert D. Bailey
Name:			A. Robert D. Bailey
Title:			Executive Vice President and Chief Legal Officer

Date: December 22, 2025

FAQ

What change does Bausch + Lomb (BLCO) report in this 8-K/A filing?

The filing updates committee assignments for two new directors. It specifies that Eduardo C. Alfonso, MD joins the Science and Technology Committee and Steven H. Collis joins the Talent and Compensation Committee, both effective January 1, 2026, refining previously announced board changes.

Who is joining Bausch + Lomb’s Science and Technology Committee according to the 8-K/A?

Eduardo C. Alfonso, MD is joining the Science and Technology Committee. The board approved his committee appointment on December 22, 2025, with effectiveness starting January 1, 2026, following his earlier disclosed appointment to Bausch + Lomb Corporation’s board of directors.

Which Bausch + Lomb board committee will Steven H. Collis serve on?

Steven H. Collis will serve on the Talent and Compensation Committee. The board confirmed this committee role on December 22, 2025, with the appointment effective January 1, 2026, aligning his responsibilities with compensation and talent oversight at Bausch + Lomb.

Why did Bausch + Lomb (BLCO) file an Amendment No. 1 to its prior 8-K?

The amendment was filed to add specific committee assignments for two new directors. It supplements an earlier current report that only announced their board appointments, now clarifying how they will serve on key board committees from January 1, 2026.

When do the new Bausch + Lomb director committee appointments become effective?

Both committee appointments become effective January 1, 2026. On that date, Eduardo C. Alfonso, MD joins the Science and Technology Committee and Steven H. Collis joins the Talent and Compensation Committee, formalizing their roles within the company’s board governance framework.

Who signed the Bausch + Lomb 8-K/A related to board committee appointments?

The report was signed by A. Robert D. Bailey, Executive Vice President and Chief Legal Officer. His signature, dated December 22, 2025, confirms that Bausch + Lomb authorized and submitted this amendment detailing the updated director committee assignments.